Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 2025 Annual Report: Key Highlights and Investor Insights

1. Landmark Achievements and Strategic Highlights

• Successful STAR Market Listing: In 2025, Biocytogen Pharmaceuticals achieved a pivotal milestone by listing on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, marking its official return from the H-share market to the A-share market. This transition is seen as a key foundation for the company’s large-scale future development.
• Record Financial Performance: The company reported a revenue of RMB 1,378.8 million, up by approximately 40.6% year-on-year. Net profit soared to RMB 173.2 million, a staggering increase of 416.4% compared to 2024, signaling Biocytogen’s entry into a phase of scaled profitability.
• Strong R&D Commitment: R&D expenses reached RMB 438.1 million, over 30% of revenue, underscoring the company’s continuous innovation-driven growth strategy.

2. Financial Performance and Capital Structure

• Profit and Loss: Gross profit for 2025 reached RMB 1,045.6 million, compared to RMB 761.5 million in 2024. Profit before tax was RMB 188 million, with total comprehensive income for the year at RMB 178.9 million.
• Balance Sheet Strength: Total assets stood at RMB 3,724.4 million, with net assets of RMB 2,179.5 million, up from RMB 838.6 million in 2024. The company’s equity base was significantly bolstered by the A-share listing.
• No Dividend Declared: The Board did not declare any dividend for 2025, citing the need to retain earnings for further expansion and operational use. There is currently no dividend policy in place, and future payouts will depend on distributable profits and capital requirements.
• Capital Raising: The company successfully raised RMB 1,144.1 million net from the A-share issuance in December 2025, with all net proceeds from the previous H-share global offering fully utilized by 2024.

3. Operational and Governance Developments

• Corporate Governance: The company continued to comply with the highest standards of corporate governance. However, a deviation existed as Dr. Shen Yuelei served both as Chairman and CEO, contrary to the recommended separation of these roles.
• Board Independence: The Board included at least three independent non-executive directors, satisfying listing rules, and all were confirmed as independent during the reporting period.
• Risk Management: Biocytogen implemented comprehensive risk management frameworks and internal controls, with regular reviews and training in domestic and international compliance, data privacy, and operational risks.
• Shareholder Communication: The company emphasized ongoing dialogue with shareholders via its website, general meetings, and prompt disclosures. No pre-emptive rights exist for new share issues under the Articles of Association or PRC law.
• Major Shareholders: The immediate and ultimate controlling parties are Dr. Shen Yuelei and Ms. Ni Jian, with significant stakes held through direct shares and employee shareholding platforms.

4. Share Incentive and Employee Schemes

• Share Award Scheme: The company operates share award and share incentive schemes for directors, management, and employees. As of December 31, 2025, the underlying shares for awards to directors and senior management represented 6.5% of total issued share capital.
• Remuneration: Director and senior management remuneration is performance-based, considering market benchmarks and individual contributions.

5. Regulatory and Market Risks

• Risks Identified: The company faces a range of risks, including regulatory changes, competition, reliance on key personnel, intellectual property protection, and macroeconomic factors such as currency and interest rate fluctuations.
• Geopolitical and Policy Risks: Potential impacts from US-China relations, PRC regulatory shifts, and cross-border data and scientific resource restrictions are acknowledged as material uncertainties for future operations.
• Financial Exposures: Sensitivity analysis shows moderate exposure to interest rate and foreign exchange movements, with detailed risk management policies in place.

6. Notable Events and Forward Outlook

• Board Changes: On February 12, 2026, Dr. Liu Hongkang was appointed as a non-executive director and joined the Audit and Strategy Development Committees.
• No Material Subsequent Events: Other than disclosed board changes, no material events occurred after year-end to affect the company’s prospects.
• Future Plans: The company remains committed to innovation-led growth, large-scale development, and international expansion, aiming to become a global leader in new drug discovery.

7. Price-Sensitive and Shareholder-Relevant Information

• Transition to A-Share Market: The successful A-share listing and significant capital raised may impact liquidity, valuation, and investor composition.
• Profitability Milestone: The shift from years of losses to substantial profitability is highly price-sensitive and could lead to re-rating of the stock.
• No Dividend Policy: The continued retention of earnings for growth, despite profitability, may have mixed implications for different investor classes.
• Large Share Incentive Allocations: The material portion of share capital reserved for incentive schemes may affect dilution and future earnings per share.
• Regulatory Risks: Ongoing compliance with evolving PRC and international regulations, particularly around data, scientific resources, and corporate governance, remains a key area for investors to monitor.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult professional advisors and review the full annual report for detailed disclosures and risk factors before making investment decisions. The information herein is based on the company’s 2025 annual report and may be subject to updates, amendments, or corrections. The author and publisher do not assume responsibility for investment losses related to the use of this information.

View BIOCYTOGEN-B Historical chart here